These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17724838)

  • 21. [Drugs against symptomatic, benign prostatic hyperplasia].
    Johansen TE
    Tidsskr Nor Laegeforen; 2002 Oct; 122(26):2544-5. PubMed ID: 12522881
    [No Abstract]   [Full Text] [Related]  

  • 22. Benign prostatic hyperplasia--review of treatment options.
    Oehlke KJ; Branaugh ML
    S D Med; 2009 May; 62(5):202-3. PubMed ID: 19489345
    [No Abstract]   [Full Text] [Related]  

  • 23. Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons.
    Wise GJ; Md EO
    Curr Urol Rep; 2001 Aug; 2(4):285-91. PubMed ID: 12084253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug treatment for benign prostatic hyperplasia. To interpret PSA concentrations in patients taking finasteride, multiply them by two.
    Taneja S
    BMJ; 1997 Aug; 315(7104):371. PubMed ID: 9270475
    [No Abstract]   [Full Text] [Related]  

  • 25. Benign prostatic hyperplasia: natural history, endocrine pathogenesis, and medical treatment with finasteride.
    Sherwood LM
    Mt Sinai J Med; 1996 Jan; 63(1):1-9. PubMed ID: 8935843
    [No Abstract]   [Full Text] [Related]  

  • 26. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.
    Andersen JT; Nickel JC; Marshall VR; Schulman CC; Boyle P
    Urology; 1997 Jun; 49(6):839-45. PubMed ID: 9187688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
    Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
    Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.
    Harrison RH
    J Urol; 2000 Nov; 164(5):1670-1. PubMed ID: 11203073
    [No Abstract]   [Full Text] [Related]  

  • 29. Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.
    Nehra A
    BJU Int; 2005 Aug; 96(3):237-43. PubMed ID: 16042709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Can J Urol; 2005 Feb; 12(1):2508-9; author reply 2509-10. PubMed ID: 15777487
    [No Abstract]   [Full Text] [Related]  

  • 31. Benign prostatic hypertrophy.
    Geller J
    Curr Ther Endocrinol Metab; 1997; 6():586-93. PubMed ID: 9174812
    [No Abstract]   [Full Text] [Related]  

  • 32. [Benign prostatic hyperplasia--its treatment with Proscar].
    Panchev P; Neĭkov K; Simeonov P
    Khirurgiia (Sofiia); 1996; 49(1):15-8. PubMed ID: 8975081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
    MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some remarks on the epidemiology of acute urinary retention.
    Boyle P
    Arch Ital Urol Androl; 1998 Apr; 70(2):77-82. PubMed ID: 9616984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
    Wessells H; Roy J; Bannow J; Grayhack J; Matsumoto AM; Tenover L; Herlihy R; Fitch W; Labasky R; Auerbach S; Parra R; Rajfer J; Culbertson J; Lee M; Bach MA; Waldstreicher J;
    Urology; 2003 Mar; 61(3):579-84. PubMed ID: 12639651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of benign prostatic hypertrophy].
    Romics I
    Orv Hetil; 2003 Nov; 144(45):2229-30. PubMed ID: 14686009
    [No Abstract]   [Full Text] [Related]  

  • 37. Analyzing finasteride data.
    Frankel S
    Neurourol Urodyn; 1995; 14(6):619-24. PubMed ID: 8750380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraoperative floppy-iris syndrome and finasteride intake.
    Issa SA; Dagres E
    J Cataract Refract Surg; 2007 Dec; 33(12):2142-3. PubMed ID: 18053919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finasteride: a steroid-unsparing drug?
    Persey M; Payne L; Webley M
    Rheumatology (Oxford); 1999 Mar; 38(3):285. PubMed ID: 10325672
    [No Abstract]   [Full Text] [Related]  

  • 40. [Benign prostatic hyperplasia: patients' perception of medical treatment and their expectations. Results of a french survey involving patients treated with finasteride].
    Teillac P
    Therapie; 2002; 57(5):473-83. PubMed ID: 12611202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.